Lijo Illipparambil

Lijo Illipparambil practices at Temple University Hospital - Main Campus in Philadelphia, Pennsylvania.

Lijo Illipparambil's NPI, 1912360686, was assigned on March 31, 2016. Lijo Illipparambil holds Pennsylvania license MD477547.

Lijo Illipparambil's primary practice is Temple University Hospital - Main Campus, at 3401-41 N Broad St, Philadelphia, PA 19140 in Philadelphia County. The practice phone is (215) 707-5303.

Lijo Illipparambil's primary practice is Temple University Hospital - Main Campus in Philadelphia, Pennsylvania. Lijo Illipparambil is also affiliated with Temple University Hospital. The medical group on file is Temple Faculty Physicians. Dmand AI also links Lijo Illipparambil to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Lijo Illipparambil practices, 2 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Lijo Illipparambil's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Lijo Illipparambil is licensed in Pennsylvania.

CMS data shows 267 Medicare services from Lijo Illipparambil across 6 procedure codes in 2024, for 175 Medicare patients. Medicare paid $35,036 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 175 Medicare patients who saw Lijo Illipparambil in 2024. The largest group is 65 to 74, with 100 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 49% are also on Medicaid. Their average risk score is 3.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Lijo Illipparambil's median patient age at 67, with 58% women.

In 2024, Lijo Illipparambil wrote 686 Medicare Part D claims for 118 patients. 36% of them were for generic drugs. CMS names the drug for 585 of them, across 16 drugs with 11 or more claims each, at $166,306 in total drug cost. In 2023, CMS named 319 claims across 11 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Lijo Illipparambil for performance year 2024, reported as part of a group. Lijo Illipparambil accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Lijo Illipparambil as offering telehealth.

Dmand AI links 2 papers to Lijo Illipparambil, published from 2021 to 2023. Lijo Illipparambil's most frequent co-authors are Sandhya Khurana, MBBS, Tetsuro Maeda, MD and Michelle Lynne Malnoske, MD.

CMS Open Payments shows 2 general payments to Lijo Illipparambil from 2 drug and device companies from 2023 to 2024. Food and beverage make up the largest share, 100% of the total. Inari Medical, Inc. paid the most, $184.